CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
28 December 2023 - 8:30AM
CVRx, Inc. (“CVRx”), a commercial-stage medical device company
focused on developing, manufacturing and commercializing innovative
neuromodulation solutions for patients with cardiovascular
diseases, today announced that the management team will present at
the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday,
January 10, 2024. The Company is scheduled to present at 3:45pm
Pacific Time the same day via webcast.
A live audio webcast of the conference presentation will be
available online at the investor relations page of the Company’s
website at ir.cvrx.com. A replay of the webcast will be archived on
the website for approximately 30 days.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on
developing, manufacturing and commercializing innovative
neuromodulation solutions for patients with cardiovascular
diseases. Barostim™ is the first medical technology approved by FDA
that uses neuromodulation to improve the symptoms of patients with
heart failure. Barostim is an implantable device that delivers
electrical pulses to baroreceptors located in the wall of the
carotid artery. The therapy is designed to restore balance to the
autonomic nervous system and thereby reduce the symptoms of heart
failure. Barostim received the FDA Breakthrough Device designation
and is FDA-approved for use in heart failure patients in the U.S.
It has also received the CE Mark for heart failure and resistant
hypertension in the European Economic Area. To learn more about
Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike VallieICR
Westwicke443-213-0501ir@cvrx.com
Media Contact:
Laura O’NeillFinn
Partners402-499-8203laura.oneill@finnpartners.com
CVRx (NASDAQ:CVRX)
Historical Stock Chart
From May 2024 to Jun 2024
CVRx (NASDAQ:CVRX)
Historical Stock Chart
From Jun 2023 to Jun 2024